{"id":54504,"date":"2023-03-06T11:07:50","date_gmt":"2023-03-06T10:07:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/eyebio-announces-first-asset-in-innovative-pipeline-of-retinal-disease-treatments-and-appoints-industry-leaders-to-executive-team\/"},"modified":"2023-03-06T11:07:50","modified_gmt":"2023-03-06T10:07:50","slug":"eyebio-announces-first-asset-in-innovative-pipeline-of-retinal-disease-treatments-and-appoints-industry-leaders-to-executive-team","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/eyebio-announces-first-asset-in-innovative-pipeline-of-retinal-disease-treatments-and-appoints-industry-leaders-to-executive-team\/","title":{"rendered":"EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team"},"content":{"rendered":"
\n

\n– Additions to EyeBio\u2019s leadership <\/i>team<\/i> include world-class disruptors with deep experience addressing urgent unmet needs in treatment of eye diseases
\n
<\/i>– EyeBio <\/i>co-founder Anthony P. Adamis, M.D., appointed chief scientific officer to lead development of the Company\u2019s ophthalmology pipeline
\n
<\/i>– Company provides details on Restoret<\/i>\u2122, which targets the Wnt pathway, as the lead asset in its <\/i>agonist antibody pipeline<\/i>, with plans <\/i>for IND <\/i>filing <\/i>in Q2 2023<\/i>\n<\/p>\n

<\/a><\/p>\n

LONDON & NEW YORK–(BUSINESS WIRE)–Eyebiotech Limited (EyeBio)<\/a>, a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to patients with sight-threatening eye diseases, today announced several appointments to its executive team, featuring prominent industry leaders who are highly skilled in the development of multi-specific antibodies and ophthalmic drugs. The Company also announced details on Restoret\u2122, the first asset in a diversified pipeline of multi-specific agonist antibodies. These developments establish the foundation to pursue the company\u2019s mission: to protect, restore, and improve vision for people who are underserved by available eye disease therapies.\n<\/p>\n

\n\u201cWe founded EyeBio to capture scientific advances and translate them into effective treatments for patients with serious eye diseases,\u201d said David Guyer, M.D., co-founder, CEO, and president of EyeBio. \u201cThe world-class team we have assembled gives us the talent and resources to continue our rapid progress and success in advancing a strong pipeline. It is a privilege to be surrounded by an elite group of leaders in ophthalmology, many of whom have been working in this space since the dawn of pharmacotherapy for eye disease.\u201d\n<\/p>\n

\nAppointments to the senior leadership team<\/b>\n<\/p>\n

\nEyeBio announced the following appointments to the senior leadership team:\n<\/p>\n

\nAnthony P. Adamis, M.D., <\/b>has been appointed chief scientific officer<\/b>. Dr. Adamis, who co-founded EyeBio in 2021 and Eyetech in 2002 with Dr. Guyer, previously served as senior vice president of Product Development and Development Innovation at Genentech, a member of The Roche Group. Over the course of his career, he has led development programs in multiple therapeutic areas and has overseen 25 U.S. Food and Drug Administration (FDA) approvals, the most recent of which was faricimab1<\/sup>, a novel anti-VEGF anti-Ang-2 bi-specific antibody for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).\n<\/p>\n

\n\u201cEyeBio is building one of the strongest ophthalmology pipelines in biopharma: Two novel and innovative agonist antibody assets, both with first-in-class and best-in-class potential,\u201d said Dr. Adamis. \u201cI am delighted to join a company that can combine such scientific potential with a global team of highly experienced ophthalmic drug developers.\u201d\n<\/p>\n

\n\u201cIt is a real pleasure to work once again with Tony Adamis, following our successful collaboration at Roche in developing Vabysmo\u00ae<\/sup>, which made a significant difference in patients\u2019 lives,\u201d commented Andreas Wallnoefer, Ph.D., partner at Jeito Capital.\n<\/p>\n

\nIn addition to Dr. Adamis, EyeBio announced senior leadership appointments that further expand its international team of executives and investors with a track record for developing ground-breaking ophthalmology therapies:\n<\/p>\n